News | January 31, 2022
Granules Pharmaceuticals concludes USFDA audit with three minor observations
The audit is a PAI for two of its product applications filed from this facility
The audit is a PAI for two of its product applications filed from this facility
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
UCB plans to submit regulatory applications in Q3 2022
Subscribe To Our Newsletter & Stay Updated
